Gemma S.
- Country
- Spain
- Department
- Neuroimaging
Research Overview
Data & Insights
Has run more than one trial at 1 of 4 partner sites.
Specializations
Alzheimer’s disease and preclinical cognitive decline
Gemma Salvadó’s clinical research is centered on Alzheimer’s disease, with a strong focus on the earliest stages of cognitive decline and the transition from preclinical Alzheimer’s disease to symptomatic impairment. Her work includes interest in amyloid-related risk states, early-onset Alzheimer’s disease, and late-onset Alzheimer’s disease.
- Preclinical Alzheimer’s disease
- Early symptomatic Alzheimer’s disease
- Autosomal dominant Alzheimer’s disease
- Intermediate and elevated amyloid burden
Her research activity reflects a therapeutic interest in identifying and tracking the earliest clinical and biological changes linked to Alzheimer-related progression.
Amyloid and tau biomarker imaging
Her neuroimaging work is strongly aligned with the study of amyloid PET and tau PET biomarkers, including characterization of tracer retention and longitudinal patterns of pathological accumulation. This places her at the intersection of molecular imaging and disease-specific therapeutic development.
- Brain amyloid deposition
- Cerebral tau aggregates
- Longitudinal biomarker progression
- Preclinical imaging signatures
Her involvement supports the use of imaging biomarkers to define neurodegenerative disease burden across the Alzheimer continuum.
Neurodegenerative diseases and tauopathies
Her clinical trial portfolio extends beyond Alzheimer’s disease to broader neurodegenerative diseases, including tauopathies and other disorders affecting the central nervous system and nervous system. This includes interest in disease entities with overlapping imaging and pathological profiles.
- Neurodegenerative disease spectrum
- Tau-related pathology
- Central nervous system diseases
- Brain diseases
Her work contributes to clinical understanding of disorders in which protein aggregation and neurodegeneration are key therapeutic targets.
Dementia and neurocognitive disorders
Gemma Salvadó is also involved in research on dementia and broader neurocognitive disorders, with attention to clinically meaningful progression and the impact of disease evolution on cognition and function. Her interests include conditions that present with early cognitive symptoms or progressive impairment.
- Dementia progression
- Neurocognitive impairment
- Clinical progression markers
- Early disease detection
Her trial activity supports therapeutic strategies aimed at delaying worsening across the dementia spectrum.
Neuroimaging in inherited and atypical brain disorders
Based in Neuroimaging at the Barcelonabeta Brain Research Center in Barcelona, her research also includes imaging-based study of atypical and inherited brain disorders such as CADASIL and other conditions within the Alzheimer continuum. This work connects molecular imaging with disease characterization in complex neurological syndromes.
- Inherited cerebral small-vessel disease
- Atypical dementia syndromes
- Biological disease characterization
- Brain imaging markers
Her clinical interests emphasize the role of imaging in defining disease expression across diverse neurological and cognitive disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.